Resistance to antibiotics: When 1+1 is not 2July 24, 2009Genetic interactions underlie multi-resistant bacteria The evolution of multiple antibiotic resistances is a global and difficult problem to eradicate. Isabel Gordo, a group leader at the Instituto Gulbenkian de Ciência (IGC)- Portugal, reports in the paper published in the latest issue of PLoS Genetics (*), that the deleterious effect associated with the acquisition of resistance by a bacteria can be suppressed by the acquisition of a new resistance to another antibiotic. These findings have direct implications for the approaches taken to tackle the problem of multi-resistance to antibiotics and in the choice of antibiotics to be administrated to patients. Acquisition of mutations is one of the ways by which bacteria become resistant to antibiotics. But this comes with a cost: although crucial for bacteria survival in a medium with antibiotics, in its absence bacteria growth rate is reduced. Although it is not possible to impaired bacteria to evolve and adapt to the environment, it is possible to choose the type of selective pressure (antibiotics) to administrate and, in this way, alter the course of evolution to our favour. This study shows the importance of knowing the costs of multi-resistance to find the best antibiotic combinations (the ones that carry more costs to the bacteria). In collaboration with two other research groups at the IGC, Isabel's team selected populations of the bacteria, Escherichia coli, showing spontaneous mutations that confer resistance to common used antibiotics (the same used in the treatment of tuberculosis). This approach allowed the team to measure the effect of genetic interactions - a phenomenon scientists call epistasis- between the alleles of the genes involved in resistance. Epistasis is considered to be one of the key issues in Biology research. Isabel describes their findings, 'To our surprise, when in a medium without antibiotics, bacteria that are carry resistance to two drugs have a higher survival rate than expected, showing a smaller cost to multiple resistance". Even more surprisingly, in some combinations (12%) the double mutants to two given antibiotics survive even better than if they were resistant to only one of the drugs. This is the worst scenario case for the host (including our species) and the best for the bacteria. This study provides the first insight into the importance of genetic interaction between random alleles in determining antibiotic resistance in bacteria. From a public health point of view, it can also explains multi-drug resistance seen in bacteria associated with many diseases, such as tuberculosis (Mycobacterium tuberculosis), for which current treatments involve combinations of the same drugs used in this study. According to Isabel: "This works shows how important it is to know the clinical history of the patient's antibiotic use as well as the specific bacteria's genotype associated with a given resistance in order to choose the appropriate treatment and obtain the best clinical outcomes". She adds: "From a more general point of view, this work uncovers the complexity associated with genomes ". Instituto Gulbenkian de Ciencia |
|||||||||||||||||||||
| Related Antibiotics Current Events and Antibiotics News Articles A Second Skin Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. Study reveals why certain drug combinations backfire Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow. New imagining technique could lead to better antibiotics and cancer drugs A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist. UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. Progress made on group B streptococcus vaccine Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. Henry Ford Hospital study: A MRSA strain linked to high death rates A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Pumpkin skin may scare away germs The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year. Deadly stomach infection rising in community settings, Mayo Clinic study finds Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile is on the rise in outpatient settings. New clinical guidelines for exacerbations in cystic fibrosis The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices. More Antibiotics Current Events and Antibiotics News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||